Focusing on investment strategies for growing life science companies, the 14th Annual BIO Investor Forum will fill the San Francisco Parc 55 Hotel with investors and innovative entrepreneurs from October 20-21, 2015. With discussion topics including venture capital funding trends and clinical trial productivity, the forum will explore past and present elements of the life sciences industry that are shaping its future.
“The BIO Investor Forum is the perfect venue for investors to connect with executives at the top fast-growing life sciences companies,” said Jim Greenwood, President and CEO, BIO. “The environment for biotech is strong right now – there has never been a better time for emerging companies to seek new funding sources.”
Included is an opportunity for an early-stage company seeking its next financing round, or a late-stage private company searching for valuable connections to take their product to the next phase to win an opportunity to do a presentation. Ten biotechs will be nominated in each of the two categories, “Early Stage Entrepreneurs” and “Late Stage Leaders”. Only 20 nominations will be accepted in total, and must be submitted by 5:00pm ET, August 18, 2015.
The agenda for this year’s program includes fireside chats with industry experts including ARCH Venture Partners Co-Founder & Managing Director, Robert T. Nelson; company presentations and the following business & therapeutic panels:
Therapeutic Panel Topics:
Report from the Frontier: Emerging Oncology Trends Bridging ASCO to ASH
Precision Medicine: Leveraging National Genomic Databases for Therapy Development (US, UK, Iceland)
Stretching Your Dollar: Methods and Tools for Increasing the Productivity of Clinical Trials
Policy Outlook””Valuation Model Implications of 21st Century Cures, IP Reform, TPP, and PDUFA VI
Business Panel Topics:
Investor Management Lessons of Fierce 15 Alumni CEOs
Venture Capital Funding Trends: BIO Analysis of Ten Years of Investment and the Gaps that Appear
BioCentury Presents: Courting Crossover Investors
2015-16 Market Outlook””Status of the IPO Appetite, M&A, Foreign Shocks, and Higher Interest Rates?
